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Abstract
Background: Isoflavones are gaining popularity as alternatives to hormone replacement therapy.
However, few guidelines exist to inform the public as to an appropriate dose. This case involves a
postmenopausal woman who experienced a hypertensive crisis while consuming a high-dose
isoflavone supplement as part of a research protocol.
Case Presentation: The participant was part of a placebo-controlled crossover trial to
investigate the potential synergism of the antioxidant activity of soy isoflavones and vitamin C.
Upon entry into the study, this healthy, well-nourished, normotensive postmenopausal woman (51
years old), consumed the first of four randomly assigned treatments (500 mg vitamin C plus 5 mg/
kg body weight soy isoflavones). During this treatment, the participant's systolic blood pressure
spiked to a recorded 226/117 mmHg, necessitating medical intervention and discontinuation of
study participation. Two plausible mechanisms for this hypertensive crisis are discussed.
Conclusion: Due to the availability and increasing popularity of soy supplements, practitioners
should be aware of the potential side effects associated with their use. Practitioners counseling
clients who are consuming soy isoflavone supplements should advise them that elevated blood
pressure may be a potential side-effect to consider and monitor.
Background
In recent years, isoflavones have increased in popularity as
an alternative to conventional hormone replacement ther-
apy for the relief of hot flashes and other symptoms asso-
ciated with menopause. Currently, isoflavones are
available as tablets, capsules, powders (particularly soy
protein powders), drinks and bars [1] as well as a compo-
nent of traditional soy foods. Typically, supplements pro-
vide 25–100 mg total isoflavones if consumed according
to package directions [1]. Yet, due to the increasing variety
of soy foods in the marketplace, consumers can easily con-
sume 100 mg or more of total isoflavones each day from
the diet alone. Although soy foods have been available for
millennia, isoflavone supplements are relatively new and
few drug/supplement or nutrient/supplement interac-
tions have been identified [1]. However, consumers
should be advised to use caution when taking isoflavone
supplements because the potential for unidentified inter-
actions does exist. This case study presents a postmeno-
pausal woman who experienced an isoflavone/nutrient
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interaction, which resulted in a hypertensive crisis requir-
ing medical intervention.
Case presentation
A 51-year-old postmenopausal non-Hispanic white
woman was treated for a hypertensive crisis at a regional
medical center in eastern Arizona. She had complained of
symptoms for one week prior to admission, including
light-headedness, headaches, and high blood pressure by
self-measurement. Ten days prior to admission, the
patient had been enrolled in a university-sponsored
research trial designed to investigate the extent to which
vitamin C and soy isoflavones, as supplements to a habit-
ual diet, could provide antioxidant effects by reducing in
vivo oxidative damage to cells, either alone or synergisti-
cally. During trial screening the patient reported typically
consuming soy or soy products twice a week; no regular
alcohol consumption; no history of hypertension or car-
diovascular disease (although there was a family history
of mild hypertension); no current medical supervision or
care for any chronic health problems; no current use of
over-the-counter or prescription medications and a rou-
tine exercise pattern of three times a week for 30–60 min-
utes. The participant weighed 175 pounds (79.5 kg),
stood 5'8" (1.73 m), with a body mass index of 26.7 kg/
m2.
Early in the research trial, the patient was randomized to
receive 500 mg vitamin C plus 5 mg/kg body weight soy
isoflavones. On trial day 3, the patient reported to the
investigators that she felt "odd" and "light-headed." At the
time, this was not attributed to the study-related supple-
ments because the participant reported experiencing infre-
quent headaches for the past 20 years. On trial days 6 and
Table 1: Vital signs and pertinent events during emergency room admission
Blood Pressure
Date Time Systolic Diastolic Heart Rate Respirations Notes
March 10 1301 226 117 87 20
1310 12 lead EKG performed Blood drawn for laboratory analyses
1334 203 115 75 18
1339 190 110 70 20 Taken to CT
1345 178 112 78 16
1349 176 100 78 18
1354 177 111 71 12
1357 177 118 72 10
1359 187 106 70 18 Medicated via IV: Labetolol HCl 20 mg Pt. stated ↓  headache
1404 162 96 67 11
1409 159 94 74 16
1414 169 111 72 15
1419 177 108 72 17
1424 181 104 73 27
1429 163 93 69 13
1434 169 97 69 15
1439 170 111 72 22
1444 162 97 84 14
1449 168 104 70 13 Pt. stated headache gone
1454 171 104 65 12
1459 166 92 69 14
1504 190 106 74 18
1509 181 107 69 34
1514 177 106 76 13
1519 163 104 71 20
1524 178 108 70 14
1529 176 106 64 20
1534 168 102 89 9
1539 162 100 70 16
1544 168 102 68 14
1549 165 102 70 12 Medicated PO: Inderal LA 80 mg
1618 179 117 69 N/A
1630 Discharged to homeBMC Women's Health 2005, 5:9 http://www.biomedcentral.com/1472-6874/5/9
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7 of the treatment period, the participant had her blood
pressure checked by an automated machine; the readings
were in the range of 140–150/92–98 mmHg vs. her usual
BP of 120/82 mmHg. Due to this unexpected occurrence,
the investigators requested that she stop consuming the
supplements and drop out of the study. The incident was
reported the university's Institutional Review Board
Research Compliance Office, and the research trial was
allowed to continue. Unbeknownst to the investigators,
the participant chose to ignore the request to discontinue
the supplements and continued to take the supplements
on trial days 8 and 9. On trial day 9 she found her BP to
be 159/110 mmHg. That night, she experienced an
intense headache, a feeling of anxiety, and difficulty sleep-
ing. Around midday on trial day 10, she stopped by a
regional medical center to have her BP checked by a med-
ical professional before going hiking. At that time, her BP
was 226/117 mmHg; she reported that "my head feels like
it is going to explode" and she was admitted to the emer-
gency room. Laboratory analyses, including a complete
blood count, metabolic panel and thyroid stimulating
hormone test, were all within normal limits. A CT scan of
the head showed no abnormalities or intracranial hemor-
rhages and a 12 lead EKG showed a normal sinus rhythm.
At this time, the participant reported to the physician a 20-
year history of chronic headaches that had resolved with
better sleep habits and a higher fluid intake. The partici-
pant was then given 20 mg of the alpha1 and beta-blocker
labetalol HCl via intravenous infusion (see Table 1). Sub-
sequent to administration of the medication, the partici-
pant's blood pressure slowly dropped below critical levels,
but did not reach normal limits. She was dismissed from
the emergency room after 3 1/2 hours with a prescription
for the non-selective beta-blocker propranolol HCl
(Inderal LA), 80 mg once a day. She was told to discon-
tinue the supplements that she was taking for the research
trial.
The patient notified the trial investigator of the hyperten-
sive event several days later. The hypertensive crisis was
reported to the university's Institutional Review Board
Research Compliance Office, and the research trial was
allowed to continue with the stipulation that all partici-
pants submit to blood pressure monitoring weekly. Later
that week, the participant's BP was measured by the pri-
mary investigator's staff and was still above normal limits.
When the participant saw a cardiologist and her regular
physician for further follow-up, no abnormalities in car-
diac function, renal function or hormone levels were
identified that could have led to the hypertensive crisis.
The participant continued on antihypertensive medica-
tions for the next 12 months and was gradually able to
decrease the dose of the medications over time.
Discussion
One plausible explanation for the hypertensive crisis
experienced by this participant is the inhibition of
monoamine oxidase by the isoflavones (e.g., daidzin,
daidzein) or their metabolites (e.g., equol). Rooke et
al.[2] and Gao et al.[3] both reported that daidzin, the
plant precursor of the mammalian metabolite daidzein,
and some of its structural analogs can inhibit mitochon-
drial monoamine oxidase in vitro. Additionally, Dewar et
al.[4] reported that equol, a mammalian metabolite of
daidzein, was an effective inhibitor of rat liver monoam-
ine oxidase in vitro. Since the soy isoflavone supplements
used in the research trial consisted of 63% (178 mg agly-
cone units/g) genistein, 28% (79.1 mg aglycone units/g)
daidzein and 9% (24.6 aglycone units/g) glycitein (per-
centages based on aglycone units), the daidzein in the
supplement may have interacted with monoamine
oxidase.
Table 2: Participant's Dietary Intake
Dinner on Day 9, 5:30 p.m.
*Yoplait fat free yogurt–12 ounces
Peanuts, salted–1/4 cup
Navel orange–1 medium
*Banana, ripe–1 medium
*Avocado, ripe–1 small
Potato chips–1 handful
Jelly beans–1/4 cup
*3 Musketeers bar–1/3 of bar
Vanilla ice cream–1/2 cup
Breakfast on Day 10, 8:00 a.m.
*Coffee–21 ounces
*Bacon–3 slices
Eggs, scrambled–2 whole
Toast–1 slice with ~1 teaspoon margarine
* signifies tyramine-containing foods
Foods from participant's Typical Diet containing tyramine or other 
pressor agents[5,6]
Balsamic vinegar–1–2 teaspoons daily
Cheddar cheese–2–4 ounces daily
Mozzarella cheese–1 ounce daily
Yogurt–16 ounces daily
Dried beans or legumes–1/2 cup daily
Coffee–17–21 ounces daily
Bananas–1 every other day
Avocado–3 times/week
Tamari sauce–1 tablespoon 2 times/week
Swiss cheese–2 ounces/week
Cured meats–1 time/week
Raisins–2–3 times/month
Spinach–2–3 times/month
Blue Cheese–2–3 times/month
Chocolate–occasionallyBMC Women's Health 2005, 5:9 http://www.biomedcentral.com/1472-6874/5/9
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Monoamine oxidase is responsible for the deamination of
monoamines, including serotonin, epinephrine,
norepinephrine, dopamine and tyramine. Its inhibition
will cause an increase in the blood levels of these com-
pounds. Since tyramine acts as a vasoconstrictor, an
increased tyramine level will cause an increase in blood
pressure [5,6]. Review of the two-day food records
recorded prior to the participant's entering the study in
addition to dietary information obtained after the hyper-
tensive event indicated the participant's normal diet typi-
cally contained multiple tyramine-containing foods. The
participant confirmed that she had consumed several
tyramine-containing foods during the study, including
the day before and the day of her emergency room admis-
sion (Table 2). Thus, the high dose of supplemental iso-
flavones [397.5 mg isoflavones (aglycone units)
containing approximately 111 mg daidzein (aglycone
units)], in conjunction with her typical moderate to high
tyramine diet, may have contributed to a monoamine oxi-
dase inhibitor-type reaction. Although the studies by
Rooke et al.[2], Gao et al. [3] and Dewar et al.[4] suggest
such a reaction might be possible, we believe this is the
first report published of a possible monoamine oxidase
inhibitor reaction and subsequent blood pressure spike
occurring  in vivo due to intake of a soy isoflavone
supplement.
A second plausible explanation for the hypertensive crisis
experienced by this participant is an imbalance in the
renin-angiotensin system, an important regulator of
blood pressure, due to the administration of the isofla-
vones. Isoflavones are known to bind to both the α  and β
estrogen receptors and exert weak estrogenic effects in
vivo [7,8]. Because angiotensinogen production by the
liver is modulated by estrogens, the assumed increase in
the serum isoflavone concentrations due to the high iso-
flavone intake may have stimulated an estrogenic
response, thereby increasing hepatic angiotensinogen
production and release into the plasma [9-11]. Once
cleaved by renin, angiotensinogen becomes angiotensin I
which is rapidly converted to angiotensin II by the angi-
otensin-converting enzyme [12]. Angiotensin II acts on
the outer layer of the zona glomerulosa of the adrenal cor-
tex, converting corticosterone to aldosterone, which sub-
sequently increases renal sodium reabsorption as well as
extracellular fluid and blood volume resulting in an
increase in blood pressure [12]. Thus, the high dose of
supplemental isoflavones consumed by this participant
may have caused an imbalance in the renin-angiotensin
system, the end result of which was the hypertensive crisis
that the participant experienced.
Conclusion
Due to the availability and increasing popularity of soy
supplements, practitioners should be aware of the poten-
tial side effects associated with their use. This case study
reports two plausible reactions, a monoamine oxidase
inhibitor-type reaction or an imbalance in the renin-angi-
otensin system, which may have occurred with consump-
tion of a high-dose isoflavone supplement resulting in the
participant experiencing a hypertensive crisis. Although
this reaction occurred within the context of a research
study, it is possible that similar reactions might occur in
general population if the dosage guidelines listed on the
soy isoflavone supplements are exceeded. Practitioners
counseling clients who are consuming soy isoflavone sup-
plements should advise them that elevated blood pressure
may be a potential side-effect to consider and monitor.
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